A Cyclin E Centered Genetic Network Contributes to Alcohol-Induced Variation in Drosophila Development
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Metastatic Adrenocortical Carcinoma Displays Higher Mutation Rate and Tumor Heterogeneity Than Primary Tumors
ARTICLE DOI: 10.1038/s41467-018-06366-z OPEN Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors Sudheer Kumar Gara1, Justin Lack2, Lisa Zhang1, Emerson Harris1, Margaret Cam2 & Electron Kebebew1,3 Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is 1234567890():,; unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37–57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs. 1 Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 2 Center for Cancer Research, Collaborative Bioinformatics Resource, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 3 Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA. Correspondence and requests for materials should be addressed to E.K. (email: [email protected]) NATURE COMMUNICATIONS | (2018) 9:4172 | DOI: 10.1038/s41467-018-06366-z | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06366-z drenocortical carcinoma (ACC) is a rare malignancy with types including primary ACC from the TCGA to understand our A0.7–2 cases per million per year1,2. -
Dysregulation of Post-Transcriptional Modification by Copy Number
Yoshikawa et al. Translational Psychiatry (2021) 11:331 https://doi.org/10.1038/s41398-021-01460-1 Translational Psychiatry ARTICLE Open Access Dysregulation of post-transcriptional modification by copy number variable microRNAs in schizophrenia with enhanced glycation stress Akane Yoshikawa1,2,ItaruKushima 3,4, Mitsuhiro Miyashita 1,5,6,KazuyaToriumi 1, Kazuhiro Suzuki 1,5, Yasue Horiuchi 1, Hideya Kawaji 7, Shunya Takizawa8,NorioOzaki 3, Masanari Itokawa1 and Makoto Arai 1 Abstract Previously, we identified a subpopulation of schizophrenia (SCZ) showing increased levels of plasma pentosidine, a marker of glycation and oxidative stress. However, its causative genetic factors remain largely unknown. Recently, it has been suggested that dysregulated posttranslational modification by copy number variable microRNAs (CNV-miRNAs) may contribute to the etiology of SCZ. Here, an integrative genome-wide CNV-miRNA analysis was performed to investigate the etiology of SCZ with accumulated plasma pentosidine (PEN-SCZ). The number of CNV-miRNAs and the gene ontology (GO) in the context of miRNAs within CNVs were compared between PEN-SCZ and non-PEN-SCZ groups. Gene set enrichment analysis of miRNA target genes was further performed to evaluate the pathways affected in PEN-SCZ. We show that miRNAs were significantly enriched within CNVs in the PEN-SCZ versus non-PEN-SCZ groups (p = 0.032). Of note, as per GO analysis, the dysregulated neurodevelopmental events in the two groups may have different origins. Additionally, gene set enrichment analysis of miRNA target genes revealed that miRNAs involved in glycation/oxidative stress and synaptic neurotransmission, especially glutamate/GABA receptor signaling, fi 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; were possibly affected in PEN-SCZ. -
Functional Test of PCDHB11, the Most Human-Specific Neuronal Surface Protein Guilherme Braga De Freitas, Rafaella Araújo Gonçalves and Matthias Gralle*
de Freitas et al. BMC Evolutionary Biology (2016) 16:75 DOI 10.1186/s12862-016-0652-x RESEARCHARTICLE Open Access Functional test of PCDHB11, the most human-specific neuronal surface protein Guilherme Braga de Freitas, Rafaella Araújo Gonçalves and Matthias Gralle* Abstract Background: Brain-expressed proteins that have undergone functional change during human evolution may contribute to human cognitive capacities, and may also leave us vulnerable to specifically human diseases, such as schizophrenia, autism or Alzheimer’s disease. In order to search systematically for those proteins that have changed the most during human evolution and that might contribute to brain function and pathology, all proteins with orthologs in chimpanzee, orangutan and rhesus macaque and annotated as being expressed on the surface of cells in the human central nervous system were ordered by the number of human-specific amino acid differences that are fixed in modern populations. Results: PCDHB11, a beta-protocadherin homologous to murine cell adhesion proteins, stood out with 12 substitutions and maintained its lead after normalizing for protein size and applying weights for amino acid exchange probabilities. Human PCDHB11 was found to cause homophilic cell adhesion, but at lower levels than shown for other clustered protocadherins. Homophilic adhesion caused by a PCDHB11 with reversion of human- specific changes was as low as for modern human PCDHB11; while neither human nor reverted PCDHB11 adhered to controls, they did adhere to each other. A loss of function in PCDHB11 is unlikely because intra-human variability did not increase relative to the other human beta-protocadherins. Conclusions: The brain-expressed protein with the highest number of human-specific substitutions is PCDHB11. -
Integrative Network-Based Approach Identifies Key Genetic Elements In
Hamed et al. BMC Genomics 2015, 16(Suppl 5):S2 www.biomedcentral.com/1471-2164/16/S5/S2 RESEARCH Open Access Integrative network-based approach identifies key genetic elements in breast invasive carcinoma Mohamed Hamed, Christian Spaniol, Alexander Zapp, Volkhard Helms* From X-meeting 2014 - International Conference on the Brazilian Association for Bioinformatics and Computational Biology Belo Horizonte, Brazil. 28-30 October 2014 Abstract Background: Breast cancer is a genetically heterogeneous type of cancer that belongs to the most prevalent types with a high mortality rate. Treatment and prognosis of breast cancer would profit largely from a correct classification and identification of genetic key drivers and major determinants driving the tumorigenesis process. In the light of the availability of tumor genomic and epigenomic data from different sources and experiments, new integrative approaches are needed to boost the probability of identifying such genetic key drivers. We present here an integrative network-based approach that is able to associate regulatory network interactions with the development of breast carcinoma by integrating information from gene expression, DNA methylation, miRNA expression, and somatic mutation datasets. Results: Our results showed strong association between regulatory elements from different data sources in terms of the mutual regulatory influence and genomic proximity. By analyzing different types of regulatory interactions, TF-gene, miRNA-mRNA, and proximity analysis of somatic variants, we identified 106 genes, 68 miRNAs, and 9 mutations that are candidate drivers of oncogenic processes in breast cancer. Moreover, we unraveled regulatory interactions among these key drivers and the other elements in the breast cancer network. Intriguingly, about one third of the identified driver genes are targeted by known anti-cancer drugs and the majority of the identified key miRNAs are implicated in cancerogenesis of multiple organs. -
Thousands of Cpgs Show DNA Methylation Differences in ACPA-Positive Individuals
G C A T T A C G G C A T genes Article Thousands of CpGs Show DNA Methylation Differences in ACPA-Positive Individuals Yixiao Zeng 1,2, Kaiqiong Zhao 2,3, Kathleen Oros Klein 2, Xiaojian Shao 4, Marvin J. Fritzler 5, Marie Hudson 2,6,7, Inés Colmegna 6,8, Tomi Pastinen 9,10, Sasha Bernatsky 6,8 and Celia M. T. Greenwood 1,2,3,9,11,* 1 PhD Program in Quantitative Life Sciences, Interfaculty Studies, McGill University, Montréal, QC H3A 1E3, Canada; [email protected] 2 Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC H3T 1E2, Canada; [email protected] (K.Z.); [email protected] (K.O.K.); [email protected] (M.H.) 3 Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC H3A 1A2, Canada 4 Digital Technologies Research Centre, National Research Council Canada, Ottawa, ON K1A 0R6, Canada; [email protected] 5 Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada; [email protected] 6 Department of Medicine, McGill University, Montréal, QC H4A 3J1, Canada; [email protected] (I.C.); [email protected] (S.B.) 7 Division of Rheumatology, Jewish General Hospital, Montréal, QC H3T 1E2, Canada 8 Division of Rheumatology, McGill University, Montréal, QC H3G 1A4, Canada 9 Department of Human Genetics, McGill University, Montréal, QC H3A 0C7, Canada; [email protected] 10 Center for Pediatric Genomic Medicine, Children’s Mercy, Kansas City, MO 64108, USA 11 Gerald Bronfman Department of Oncology, McGill University, Montréal, QC H4A 3T2, Canada * Correspondence: [email protected] Citation: Zeng, Y.; Zhao, K.; Oros Abstract: High levels of anti-citrullinated protein antibodies (ACPA) are often observed prior to Klein, K.; Shao, X.; Fritzler, M.J.; Hudson, M.; Colmegna, I.; Pastinen, a diagnosis of rheumatoid arthritis (RA). -
New Possible Targetable Genes for Future Treatment of Mixed Lineage Leukemia Senol Dogan* International Burch University, Sarajevo, Bosnia and Herzegovina
etrics iom & B B f io o l s t a a n t Dogan, J Biom Biostat 2017, 8:3 r i s u t i o c J s Journal of Biometrics & Biostatistics DOI: 10.4172/2155-6180.1000349 ISSN: 2155-6180 Research Ar ticleArticle Open Access New Possible Targetable Genes for Future Treatment of Mixed Lineage Leukemia Senol Dogan* International Burch University, Sarajevo, Bosnia and Herzegovina Abstract Aim of study: Leukemia has different subtypes, which present unique clinical and molecular characteristics. MLL (Mixed Lineage Leukemia) is one of the new different subtypes than AML and ALL. Materials and Methods: Genomic characterization is the main key understanding the differences of MLL by analysis of differential gene expression, methylation patterns and mutational spectra that were compared and analyzed between MLL and AML types (n=197). Results: According to the genomic characterization of MLL, differentially expressed 114 genes were selected and 37 of them targeted genes having more than 2 fold expression change, including HOXA9, CFH, DDX4, MSH4, MSMB, TWIST1, ZSWIM2, POU6F2. To measure the aberrant methylation is the second genomic characterization of this research because the rearrangements of MLL gene leading to aberrant methylation. The methylation data were compared between cancer and control, so high methylated genes have been detected between MLL and AML types. The methylation loci were categorized into two groups: ≥ 10 fold difference and ≥ 5 and ≤ 10 fold difference. Some of the genes high methylated more than one location such as; RAET1E, HSD17B2, RNASE11, DGK1, POU6F2, NAGS, PIK3C2G, GADL1, and KRT13. In addition to that, analysis of somatic mutation gives us that CFH has the highest point mutation 9,92%. -
SRSF6 Regulates Alternative Splicing of Genes Involved in DNA Damage Response and DNA Repair in Hela Cells
ONCOLOGY REPORTS 44: 1851-1862, 2020 SRSF6 regulates alternative splicing of genes involved in DNA damage response and DNA repair in HeLa cells XIAO YANG1, PENG ZHAN1, SHUQIANG FENG1, HE JI2, WENJIE TIAN1, MENGDI WANG3, CHAO CHENG3 and BIN SONG2 Departments of 1Urology and 2Neurosurgery, The Second Hospital of Jilin University, Changchun, Jilin 130041; 3ABLife BioBigData Institute, Wuhan, Hubei 430075, P.R. China Received October 18, 2019; Accepted June 18, 2020 DOI: 10.3892/or.2020.7750 Abstract. Alternative splicing (AS) occurs in nearly all human Introduction genes and abnormal AS has a close association with cancer. Serine and arginine-rich splicing factor 6 (SRSF6), a canonical Cancer is a major public health problem worldwide and member of the serine/arginine-rich protein family, has been is expected to be the leading cause of death and the single characterized as an important regulator of AS. However, the most important barrier to increasing life expectancy in the role of SRSF6 in regulating AS in cancers has remained to be 21st century (1). It is now understood that advanced age and fully elucidated. In the present study, the median expression of exposure to ionizing radiation may be the most important risk SRSF6 in tumors was determined to be higher compared with factors promoting carcinogenesis (2,3). Substantial research that in matched normal tissues in 13 out of 16 cancer types progress has been made in recent years to understand the basic from The Cancer Genome Atlas. To investigate the biological mechanisms underlying cancer initiation and progression effects of SRSF6 overexpression, an SRSF6-overexpression and to identify potential targets for therapeutic interven- model of HeLa cells was constructed and it was revealed tion. -
Mutations on Protein Function
Developing A Computational Approach To Investigate The Impacts of Disease Causing Mutations On Protein Function Camilla Sih Mai Pang A thesis submitted for the degree of Doctor of Philosophy January 2018 Institute of Structural and Molecular Biology University College London 2 I, Camilla Sih Mai Pang confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Camilla Sih Mai Pang January 2018 3 I dedicate this PhD thesis to my parents: Sonia Louise Pang & Peter Tak Chung Pang. 4 Abstract This project uses bioinformatics protocols to explore the impacts of non-synonymous mutations (nsSNPs) in proteins associated with diseases, including germline, rare dis- eases and somatic diseases such as cancer. New approaches were explored for deter- mining the impacts of disease-associated mutations on protein structure and function. Whilst this work has mainly concentrated on the analysis of cancer mutations, the meth- ods developed are generic and could be applied to analysing other types of disease mutations. Different types of disease causing mutations have been studied including germline diseases, somatic cancer mutations in oncogenes and tumour-suppressors, along with known activating and inactivating mutations in kinases. The proximity of disease-associated mutations has been analysed with respect to known functional sites reported by CSA, IBIS, along with predicted functional sites derived from the CATH clas- sification of domain structure superfamilies. The latter are called FunSites, and are highly conserved residues within a CATH functional family (FunFam) – which is a functionally coherent subset of a CATH superfamily. -
Neonatal-Onset Autoinflammation and Immunodeficiency Caused by Heterozygous Missense Mutation of the Proteasome Subunit Β-Type 9
medRxiv preprint doi: https://doi.org/10.1101/2021.02.01.21250077; this version posted February 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Neonatal-onset autoinflammation and immunodeficiency caused by heterozygous missense mutation of the proteasome subunit β-type 9 Nobuo Kanazawa1,2*, Hiroaki Hemmi3,4*, Noriko Kinjo5, Hidenori Ohnishi6, Jun Hamazaki7, Hiroyuki Mishima8, Akira Kinoshita8, Tsunehiro Mizushima9, Satoru Hamada5, Kazuya Hamada5, Norio Kawamoto6, Saori Kadowaki6, Yoshitaka Honda10, Kazushi Izawa10, Ryuta Nishikomori11, Miyuki Tsumura12, Yusuke Yamashita13, Shinobu Tamura13, Takashi Orimo3,14, Toshiya Ozasa3, Takashi Kato3, Izumi Sasaki3, Yuri Fukuda-Ohta3, Naoko Wakaki-Nishiyama3, Yutaka Inaba1, Kayo Kunimoto1, Satoshi Okada12, Takeshi Taketani15, Koichi Nakanishi5, Shigeo Murata7, Koh-ichiro Yoshiura8, Tsuneyasu Kaisho3 1 Department of Dermatology, Wakayama Medical University, Wakayama, Japan. 2Department of Dermatology, Hyogo College of Medicine, Hyogo, Japan. 3Department of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan. 4Laboratory of Immunology, Faculty of Veterinary Medicine, Okayama University of Science, Ehime, Japan. 5Department of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan 6Department of Pediatrics, Graduate School -
“Functional Characterization of the RNA Binding Protein RALY”
International Doctoral School in Biomolecular Sciences XXV Cycle “Functional characterization of the RNA binding protein RALY” Tutor Professor Paolo MACCHI CIBIO- University of Trento Ph.D. Thesis of Albertomaria MORO CIBIO- University of Trento Academic Year 2012-2013 To myself and my little world... INDEX 1 - Introduction ....................................................................................................... 1 1.1 The RNA-binding proteins ............................................................................. 2 1.2 The hnRNP super family ............................................................................... 5 1.2.1 Properties of hnRNPs ............................................................................ 5 1.3 RALY: a new member of hnRNPs ................................................................. 9 2 - Topic of my PhD project ................................................................................. 13 3 - Results ............................................................................................................ 15 3.1 Publication 1:............................................................................................... 15 3.2 additional results ......................................................................................... 16 3.2.1 RALY localization ................................................................................. 16 3.2.2 Polyribosome profiling .......................................................................... 20 3.2.3 The microarray